Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Gene Therapy Promise | Explore Solid Biosciences' SGT-003, a potential game-changer for Duchenne muscular dystrophy, showing robust microdystrophin expression and favorable safety profile |
Financial Fortitude | Discover how Solid Biosciences extended its cash runway into 2027, bolstering its position with a $307 million balance and strategic cost management |
Competitive Edge | Learn about Solid's proprietary capsid technology, potentially outperforming rivals like Sarepta and Pfizer in muscle targeting and reduced liver tropism |
Market Potential | Analyst price targets range from $14 to $20, reflecting optimism about SGT-003's peak sales potential of $2.5-3 billion in the U.S. DMD market |
Metrics to compare | SLDB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLDBPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.9x | −3.6x | −0.5x | |
PEG Ratio | −0.18 | 0.06 | 0.00 | |
Price/Book | 1.8x | 2.0x | 2.6x | |
Price / LTM Sales | - | 4.0x | 3.2x | |
Upside (Analyst Target) | 131.3% | 83.4% | 41.7% | |
Fair Value Upside | Unlock | 8.4% | 6.1% | Unlock |